According to the Onkopedia and ESMO guidelines, BrECADD is recommended as the standard of care for adults aged ≤60 years with newly diagnosed classical Hodgkin Lymphoma (cHL) in advanced stages. [1], [2] For very fit patients aged 61–75 years, the ESMO guidelines also endorse BrECADD as a standard treatment option. [2]
BrECADD: brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone
Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.
Adcetris® Information for healthcare professionals, www.swissmedicinfo-pro.ch
C-APROM/CH/ADCE/0096_11/2025
1. Onkopedia-Leitlinie Hodgkin Lymphom. Stand Dezember 2023. https://www.onkopedia.com/de/onkopedia/guidelines/hodgkin-lymphom/@@guideline/html/index.html (last accessed: October 2025).
2. Eyre TA, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2025:S0923-7534(25)00911-1.
